Page last updated: 2024-11-04

meclofenoxate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Meclofenoxate, also known as Centrophenoxine, is a synthetic compound that has been studied for its potential cognitive-enhancing effects. It is a derivative of dimethylaminoethanol (DMAE) and is thought to act as a cholinergic agent, increasing levels of acetylcholine in the brain. Research suggests that meclofenoxate may improve memory, attention, and learning, although more research is needed to confirm these benefits. However, some studies have shown that meclofenoxate may also have antioxidant and neuroprotective properties, potentially offering protection against age-related cognitive decline. The compound is currently marketed as a dietary supplement in some countries, but it is not approved for medical use in the United States.'

Meclofenoxate: An ester of DIMETHYLAMINOETHANOL and para-chlorophenoxyacetic acid. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4039
CHEMBL ID64545
CHEBI ID6712
SCHEMBL ID147339
MeSH IDM0003816

Synonyms (137)

Synonym
BRD-K10314788-003-04-4
en 1627
(p-chlorophenoxy)acetic acid 2-(dimethylamino)ethyl ester
analux
clophenoxate
deanol p-chlorophenoxyacetate
(p-chlorophenoxy)acetic acid .beta.-(dimethylamino)ethyl ester
meclophenoxate
(dimethylamino)ethyl p-chlorophenoxyacetate
proseryl
deanolestere
at sefen
p-chlorophenoxy acetic acid 2-(dimethylamino)ethyl ester
clofenoxin
luncidril
mucidril
2-(dimethylamino)ethyl (p-chlorphenoxy)acetate
wln: gr do1vo2n1&1
nsc169411
2-(dimethylamino)ethyl (p-chlorophenoxy)acetate
nsc-169411
meclofenoxane
lucidryl
centrophenoxine
centrofenoxina
anp 235
helfergin
cetrexin
acephene
cerebon
centrophenoxin
(dimethylamino)ethyl-4-(chlorophenoxy)acetic acid
atsephen
licidril
acetic acid, (4-chlorophenoxy)-, 2-(dimethylamino)ethyl ester
DIVK1C_000367
KBIO1_000367
einecs 200-116-3
dimethylaminoethyl-p-chlorophenoxyacetate
dimethylaminoethyl-4-chlorophenoxyacetic acid
2-(dimethylamino)ethyl(p-chlorphenoxy)acetate
meclofenoxate [inn:ban:dcf]
meclofenossato [dcit]
nsc 169411
mechlorphenoxatum
meclofenoxatum [inn-latin]
brn 1914094
p-chlorophenoxyacetic acid beta-dimethylaminoethyl ester
acetic acid, (p-chlorophenoxy)-, 2-(dimethylamino)ethyl ester
meclofenoxato [inn-spanish]
centrexin
clocete
SPECTRUM_001569
PRESTWICK3_000763
LOPAC0_000250
cas-3685-84-5
lopac-c-8773
NCGC00015279-01
NCGC00015279-02
BPBIO1_000888
PRESTWICK2_000763
IDI1_000367
BSPBIO_000806
SPECTRUM5_001416
clopenoxin
2-dimethylaminoethyl 2-(4-chlorophenoxy)acetate
(4-chlorophenoxy)acetic acid 2-(dimethylamino)ethyl ester
AB00053655
51-68-3
meclofenoxate
C08195
D00993
meclofenoxate (inn)
STK182908
2-(dimethylamino)ethyl (4-chlorophenoxy)acetate
KBIOGR_001413
KBIOSS_002049
KBIO2_004617
KBIO2_007185
NCI60_000303
KBIO2_002049
PRESTWICK0_000763
SPECTRUM2_000458
PRESTWICK1_000763
SPBIO_000536
SPECTRUM4_000837
NINDS_000367
SPBIO_002745
NCGC00162104-01
NCGC00015279-04
chebi:6712 ,
anp-235
CHEMBL64545
AKOS003657007
meclofenoxato
meclofenoxatum
c76qq2i0rg ,
meclofenossato
unii-c76qq2i0rg
(p-chlorophenoxy)aceticacid2-(dimethylamino)ethylesterhydrochloride
A823409
CCG-204345
NCGC00015279-05
NCGC00015279-03
meclofenoxate [inn]
meclofenoxate [who-dd]
dimethylaminoethyl p-chlorophenoxyacetate
meclofenoxate [mi]
SCHEMBL147339
2-(dimethylamino)ethyl 2-(4-chlorophenoxy)acetate
helfergin (salt/mix)
atsephen (salt/mix)
2-(dimethylamino)ethyl p-chlorophenoxyacetate
proserout (salt/mix)
lutiaron (salt/mix)
marucotol (salt/mix)
XZTYGFHCIAKPGJ-UHFFFAOYSA-N
nsc 4268 (salt/mix)
2-(dimethylamino)ethyl-4-(chlorophenoxy)acetate
2-(dimethylamino)ethyl (4-chlorophenoxy)acetate #
meclofenoxate hydrochloride (salt/mix)
brenal (salt/mix)
at sefen (salt/mix)
centrofenoxin (salt/mix)
centrophenoxine (salt/mix)
lucidril (salt/mix)
DTXSID9046940
AB00053655_09
SBI-0050238.P003
DB13758
Q421147
BRD-K10314788-003-07-7
SDCCGSBI-0050238.P004
NCGC00015279-15
analux; cph; cerebon; cetrexin; clocete
acetic acid, 2-(4-chlorophenoxy)-, 2-(dimethylamino)ethyl ester
EN300-57783

Research Excerpts

Overview

Meclofenoxate hydrochloride is a psychostimulant in the nootropic agent group. It is approved for traumatic cataphora, alcoholic poisoning, anoxia neonatorum, and children's enuresis in China.

ExcerptReferenceRelevance
"Meclofenoxate hydrochloride is a psychostimulant in the nootropic agent group available in capsule and tablet formulations approved for traumatic cataphora, alcoholic poisoning, anoxia neonatorum, and children's enuresis in China. "( Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study.
Hu, Q; Ji, HJ; Wang, GJ; Wu, DW; Xiao, DW; Yao, J; Zou, JJ, 2008
)
2.02

Effects

ExcerptReferenceRelevance
"Meclofenoxate has been shown to increase cerebral cholinergic activity."( Meclofenoxate therapy in tardive dyskinesia: a preliminary report.
Fukuda, T; Igata, A; Imamura, K; Izumi, K; Koja, T; Nomoto, M; Shimizu, T; Sonoda, H; Tominaga, H, 1986
)
2.44

Treatment

Meclofenoxate treatment had no consistent effect on the activities of the enzymes studied. Treatment for 5 days had an even more pronounced inhibitory effect on PTZ kindling.

ExcerptReferenceRelevance
"Meclofenoxate treatment had no consistent effect on the activities of the enzymes studied."( Changes in murine tissue concentrations of dolichol and dolichol derivatives associated with age.
Daniels, I; Hemming, FW, 1990
)
1
"3. Meclofenoxate treatment caused an increase of muscarinic receptor affinity and a decrease of the binding capacity in the cerebral cortex and hypothalamus and an increase of the binding affinity in the striatum and hippocampus."( Effect of the combination of the benzodiazepine tranquilizer medazepam and the nootropic agent meclofenoxate on the activity of rat brain muscarinic receptors.
Petkov, VD; Popova, JS, 1990
)
1.01
"Meclofenoxate treatment for 5 days had an even more pronounced inhibitory effect on PTZ kindling."( Effect of meclofenoxate on pentylenetetrazol kindling in albino rats.
Genkova, M; Georgiev, V; Lazarova, M; Markovska, V; Petkov, VD, 1987
)
1.4

Pharmacokinetics

ExcerptReferenceRelevance
"The aim of this study was to compare the pharmacokinetic properties and bioequivalence of the capsule (test) and tablet (reference) formulations of meclofenoxate hydrochloride 200 mg in healthy Chinese volunteers."( Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study.
Hu, Q; Ji, HJ; Wang, GJ; Wu, DW; Xiao, DW; Yao, J; Zou, JJ, 2008
)
0.78

Dosage Studied

ExcerptRelevanceReference
"The influence of centrophenoxin (meclofenoxate) administration in a high daily dosage of 3 grams has been investigated in 10 persons with a mean age of 64 throughout 12 months."( [Influence of centrophenoxin administered for one year in high dose on maximal oxygen consumption in aged persons (author's transl)].
Schlick, W; Schmid, P, 1979
)
0.54
" With the dosage employed neurons of the central nervous system showed in all animals a significant reduction of lipofuscin pigment."( [Centrophenoxin-induced dissolution and removal of lipofuscin. An electron microscopic study (author's transl)].
Glees, P; Spoerri, PE, 1975
)
0.25
"There is a report given about the effect of Cerutil (Centrophenoxin) at an enteral dosage of 1250 mg/day over a time of eight weeks, applied with 31 patients with references for a cerebral insufficiency conditional on involution."( [Treatment results with Cerutil in age-related cerebral insufficiency in general medicine].
Richter, K,
)
0.13
" A dosage of 80 mg/Kg produced greater changes than a 120 mg/Kg dosage."( Effect of centrophenoxine on the antioxidative enzymes in various regions of the aging rat brain.
Pathak, DN; Roy, D; Singh, R, 1983
)
0.27
"Senile white rats were treated with centrophenoxine at a dosage of 100 mg/Kg body weight/day for 60 days intraperitoneally."( Cytochemical interaction of nucleolus and cytoplasm in the Purkinje cells of senile white rats under the influence of centrophenoxine.
Patro, IK; Sharma, SP, 1984
)
0.27
" The sensors were used successfully for the determination of I and II in laboratory prepared mixtures with their degradation products, in pharmaceutical dosage forms and in plasma."( Stability-indicating electrochemical methods for the determination of meclophenoxate hydrochloride and pyritinol dihydrochloride using ion-selective membrane electrodes.
El-Bardicy, MG; El-Sayed, MA; El-Tarras, MF; Lotfy, HM, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency25.11890.35487.935539.8107AID624146
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency21.19230.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency42.56150.425612.059128.1838AID504536
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.97620.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.25890.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency13.45810.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID158688Inhibitory activity against Plasmodium falciparum1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis.
AID119565Antihypoxic effect by the survival time (SVT) in mice at a dose of 3 mg/kg administered intravenously in mice1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID119554Antihypoxic effect tested by the survival time (SVT) in mice at a dose of 100 mg/kg1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID119402Time of recovery of spontaneous movement (SMT) in seconds was measured after administration of 200 mg/kg perorally in mice for the promotional effect on recovery from coma1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID119185Time of recovery of righting reflux (RRT) in seconds was measured after administration of 200 mg/kg perorally in mice for the promotional effect on recovery from coma1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (387)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990311 (80.36)18.7374
1990's40 (10.34)18.2507
2000's16 (4.13)29.6817
2010's12 (3.10)24.3611
2020's8 (2.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (4.67%)5.53%
Reviews16 (3.56%)6.00%
Case Studies7 (1.56%)4.05%
Observational0 (0.00%)0.25%
Other406 (90.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Impact of Coenzyme Q10 and Meclofenoxate on Frequency and Severity of Hepatic Encephalopathy [NCT03961087]300 participants (Anticipated)Interventional2019-05-23Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]